Clinical experiment designed to assess clinical efficacy targeting GLP in human. Primary outcome: Validate GLP-1 Agonist Neuroprotection Mechanism in PD
Description
GLP-1 Agonist Neuroprotection Mechanism in PD
Background and Rationale
Parkinson's disease (PD) is characterized by progressive dopaminergic neurodegeneration in the substantia nigra, leading to motor dysfunction and cognitive decline. Recent preclinical evidence suggests that GLP-1 receptor agonists, originally developed for diabetes treatment, exhibit neuroprotective properties through multiple mechanisms including anti-inflammatory effects, mitochondrial stabilization, and promotion of neuronal survival pathways. This randomized, double-blind, placebo-controlled clinical trial aims to elucidate the specific neuroprotective mechanisms of GLP-1 agonists in PD patients while establishing their therapeutic efficacy. The study will employ a comprehensive approach combining neuroimaging, biomarker analysis, and functional assessments to validate mechanistic hypotheses generated from preclinical models. Participants will receive either exenatide (a GLP-1 receptor agonist) or placebo over 48 weeks, with detailed monitoring of dopaminergic function via DaTscan SPECT imaging, inflammatory markers, oxidative stress indicators, and clinical motor/cognitive outcomes....
GLP-1 Agonist Neuroprotection Mechanism in PD
Background and Rationale
Parkinson's disease (PD) is characterized by progressive dopaminergic neurodegeneration in the substantia nigra, leading to motor dysfunction and cognitive decline. Recent preclinical evidence suggests that GLP-1 receptor agonists, originally developed for diabetes treatment, exhibit neuroprotective properties through multiple mechanisms including anti-inflammatory effects, mitochondrial stabilization, and promotion of neuronal survival pathways. This randomized, double-blind, placebo-controlled clinical trial aims to elucidate the specific neuroprotective mechanisms of GLP-1 agonists in PD patients while establishing their therapeutic efficacy. The study will employ a comprehensive approach combining neuroimaging, biomarker analysis, and functional assessments to validate mechanistic hypotheses generated from preclinical models. Participants will receive either exenatide (a GLP-1 receptor agonist) or placebo over 48 weeks, with detailed monitoring of dopaminergic function via DaTscan SPECT imaging, inflammatory markers, oxidative stress indicators, and clinical motor/cognitive outcomes. Key innovations include the integration of advanced neuroimaging with molecular biomarker profiles to establish direct correlations between GLP-1 pathway activation and neuroprotection in humans. The study will also investigate whether GLP-1 agonists can slow disease progression by measuring changes in striatal dopamine transporter density, a validated marker of dopaminergic neuron integrity. Secondary analyses will focus on identifying patient subgroups most responsive to GLP-1-based neuroprotection and characterizing the temporal dynamics of therapeutic response. This research has significant translational implications, potentially establishing GLP-1 agonists as disease-modifying therapies for PD and providing mechanistic insights applicable to other neurodegenerative conditions.
This experiment directly tests predictions arising from the following hypotheses:
Vagal Afferent Microbial Signal Modulation
AMPK hypersensitivity in astrocytes creates enhanced mitochondrial rescue responses
Mitochondrial Transfer Pathway Enhancement
TFAM overexpression creates mitochondrial donor-recipient gradients for directed organelle trafficking
Phase 1 (Weeks 0-4): Recruit 120 early-stage PD patients (Hoehn-Yahr stages 1-2.5). Obtain informed consent and conduct baseline assessments including MDS-UPDRS, Montreal Cognitive Assessment, DaTscan SPECT imaging, and blood collection for biomarker analysis (inflammatory cytokines IL-1β, TNF-α, IL-6; oxidative stress markers 8-OHdG, MDA; GLP-1 pathway components). Phase 2 (Weeks 4-52): Randomize participants 1:1 to subcutaneous exenatide 2mg weekly or matched placebo. Conduct safety monitoring every 4 weeks with adverse event documentation and vital signs. Perform interim assessments at weeks 12, 24, and 36 including MDS-UPDRS Part III, cognitive testing, and biomarker sampling. Phase 3 (Week 52): Conduct comprehensive endpoint evaluation including repeat DaTscan SPECT, full clinical battery, and biomarker analysis. Perform CSF sampling in consenting participants (target n=60) for neuroinflammatory markers and α-synuclein species. Phase 4 (Weeks 52-56): Complete safety follow-up and data analysis. Primary imaging analysis will quantify striatal dopamine transporter binding using validated ROI methods. Biomarker analysis will employ multiplex immunoassays and mass spectrometry. Statistical analysis will use mixed-effects models accounting for baseline characteristics, with intention-to-treat and per-protocol populations analyzed separately.
Expected Outcomes
1. Exenatide treatment will slow decline in striatal dopamine transporter binding by 40% compared to placebo (mean annual decline 3% vs 5%, p<0.05)
2. Inflammatory biomarkers (IL-1β, TNF-α) will decrease by 25-35% in the exenatide group while increasing 10-15% in placebo group (between-group difference p<0.01)
3. Motor function decline (MDS-UPDRS Part III) will be reduced by 30% in exenatide group compared to placebo over 48 weeks (mean change +4 vs +8 points, p<0.05)
4. Oxidative stress markers will show 20-30% reduction in exenatide group with correlation coefficient >0.6 between biomarker changes and imaging outcomes
5. Cognitive function will be preserved in exenatide group with MoCA scores stable (±1 point) versus 2-3 point decline in placebo group (p<0.05)
6. CSF α-synuclein oligomer levels will decrease by 25% in exenatide group while remaining stable in placebo group (between-group difference p<0.05)
Phase 1 (Weeks 0-4): Recruit 120 early-stage PD patients (Hoehn-Yahr stages 1-2.5). Obtain informed consent and conduct baseline assessments including MDS-UPDRS, Montreal Cognitive Assessment, DaTscan SPECT imaging, and blood collection for biomarker analysis (inflammatory cytokines IL-1β, TNF-α, IL-6; oxidative stress markers 8-OHdG, MDA; GLP-1 pathway components). Phase 2 (Weeks 4-52): Randomize participants 1:1 to subcutaneous exenatide 2mg weekly or matched placebo. Conduct safety monitoring every 4 weeks with adverse event documentation and vital signs. Perform interim assessments at weeks 12, 24, and 36 including MDS-UPDRS Part III, cognitive testing, and biomarker sampling.
...
Phase 1 (Weeks 0-4): Recruit 120 early-stage PD patients (Hoehn-Yahr stages 1-2.5). Obtain informed consent and conduct baseline assessments including MDS-UPDRS, Montreal Cognitive Assessment, DaTscan SPECT imaging, and blood collection for biomarker analysis (inflammatory cytokines IL-1β, TNF-α, IL-6; oxidative stress markers 8-OHdG, MDA; GLP-1 pathway components). Phase 2 (Weeks 4-52): Randomize participants 1:1 to subcutaneous exenatide 2mg weekly or matched placebo. Conduct safety monitoring every 4 weeks with adverse event documentation and vital signs. Perform interim assessments at weeks 12, 24, and 36 including MDS-UPDRS Part III, cognitive testing, and biomarker sampling. Phase 3 (Week 52): Conduct comprehensive endpoint evaluation including repeat DaTscan SPECT, full clinical battery, and biomarker analysis. Perform CSF sampling in consenting participants (target n=60) for neuroinflammatory markers and α-synuclein species. Phase 4 (Weeks 52-56): Complete safety follow-up and data analysis. Primary imaging analysis will quantify striatal dopamine transporter binding using validated ROI methods. Biomarker analysis will employ multiplex immunoassays and mass spectrometry. Statistical analysis will use mixed-effects models accounting for baseline characteristics, with intention-to-treat and per-protocol populations analyzed separately.
Expected Outcomes
1. Exenatide treatment will slow decline in striatal dopamine transporter binding by 40% compared to placebo (mean annual decline 3% vs 5%, p<0.05)
2. Inflammatory biomarkers (IL-1β, TNF-α) will decrease by 25-35% in the exenatide group while increasing 10-15% in placebo group (between-group difference p<0.01)
3. Motor function decline (MDS-UPDRS Part III) will be reduced by 30% in exenatide group compared to placebo over 48 weeks (mean change +4 vs +8 points, p<0.05)
4.
...
1. Exenatide treatment will slow decline in striatal dopamine transporter binding by 40% compared to placebo (mean annual decline 3% vs 5%, p<0.05)
2. Inflammatory biomarkers (IL-1β, TNF-α) will decrease by 25-35% in the exenatide group while increasing 10-15% in placebo group (between-group difference p<0.01)
3. Motor function decline (MDS-UPDRS Part III) will be reduced by 30% in exenatide group compared to placebo over 48 weeks (mean change +4 vs +8 points, p<0.05)
4. Oxidative stress markers will show 20-30% reduction in exenatide group with correlation coefficient >0.6 between biomarker changes and imaging outcomes
5. Cognitive function will be preserved in exenatide group with MoCA scores stable (±1 point) versus 2-3 point decline in placebo group (p<0.05)
6. CSF α-synuclein oligomer levels will decrease by 25% in exenatide group while remaining stable in placebo group (between-group difference p<0.05)